Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of t-lymphocyte in human bladder tumor cell s in vitro

Cancer Investigation

Volumn 27, Issue 9, 2009, Pages 909-917

  Li, Yong Gang ^a   Wang, Zhi Ping ^a   Tian, Jun Qiang ^a   Tian, Bin Qiang ^a   Rodrigues, Ronald ^b   Shang, Pan Feng ^a   Zhang, Tao ^a  

^a LANZHOU UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder and prostrate cancer; Gene expression; Therapy; Tumor immunology

Indexed keywords

CHEMOKINE; INTERLEUKIN 2;

APOPTOSIS; ARTICLE; BLADDER TUMOR; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; WESTERN BLOTTING;

APOPTOSIS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL21; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 70350180213     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900802375746     Document Type: Article

References (36)

1. Zhong, H.; Shurin, M.R.; Han, B. Optimizing dendritic cell-based immunotherapy for cancer. Exp Rev Vaccines 2007, 6, 333-345.
2. Nabekura, T.; Nagasawa, T.; Nakauchi, H. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.Cancer Immunol Immunother 2007.
3. Chang, H.W.; Chow, Y.H.; Chong, P.; Sia, C. The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus. Rev Diabet Stud 2007, 4, 68-76.
4. van der Velden, A.M.; Claessen, A.M.; van Velzen-Blad, H. Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon. Bone Marrow Transplant 2007, 40, 261-266.
5. Liang, C.M.; Ye, S.L.; Zhong, C.P.; Zheng, N. More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC. Mol Immunol 2007, 44, 3797-3804.
6. Tian, J.Q.;Wang, Z.P.; Rodriguez, R. In vitroenhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Urology 2006, 67, 1093-1098.
7. Carmichael, J.; DeGraff, W.G.; Gazdar, A.F.; Minna, J.D.; Mitchell, J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay:assessment of chemosensitivity testing. Cancer Res 1987, 47, 936-942. (Pubitemid 17027905)
8. Beharier, O.; Etzion, Y.; Katz, A.; Friedman, H.; Tenbosh, N.; Zacharish, S.; Bereza, S.; Goshen, U.; Moran, A. Cross-talk between L-type calcium channels and ZnT-1, a new player in ratedependent cardiac electrical remodeling. Cell Calcium 2007, 42, 71-82.
9. Maitre, N.; Brown, J.M.; Demcheva, M. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res 1999, 5, 1173-1182.
10. Lee, J.; Lee, H.-J.; Park, J.-D. Anti-cancer activity of highly purified sulfur in immortalized and malignant human oral keratinocytes. Toxicol In Vitro 2007.
11. Kim, J.W.; Ferris, R.L.;Whiteside, T.L.; et al. Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. J Clin Cancer Res 2005, 11, 7901-7910.
12. Cavanagh, L.L.; Von Andrian, U.H. Travellers in many guises: the origins and destinations of dendritic cells. Immunol Cell Biol 2002, 80, 448-462.
13. Gabrilovich, D.I.; Chen, H.L.; Girgis, K.R.; Cunningham, H.T.; Meny, G.M.; Nadaf, S.; Kavanaugh, D.; Carbone, D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2, 1096-1103.
14. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
15. Inaba, K.;Witmer-Pack, M.; Inaba, M.; Hathcock, K.S.; Sakuta, H.; Azuma, M.; Yagita, H.; Okumura, K.; Linsley, P.S.; Ikehara, S.; et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situand during maturation in vitro. J ExpMed 1994, 180, 1849-1860.
16. Waldmann, T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6, 595-601.
17. Fyfe, G.; Fisher, R.I.; Rosenberg, S.A.; Sznol, M.; Parkinson, D.R.; Louie, A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13, 688.
18. Sharma, S.; Stolina, M.; Luo, J.; Strieter, R.M.; Burdick, M.; Zhu, L.X.; Batra, R.K.; Dubinett, S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000, 164, 4558-4563.
19. Sharma, S,; Yang, S.K. SLC/CCL21-mediated anti-tumor responses require IFNã, MIG/CXCL9, and IP-10/CXCL10. Mol Cancer 2003, 15, 22.
20. Kirk, C.J.; Hartigan-O'Connor, D.; Nickoloff, B.J.; Chamberlain, J.S.; Giedlin, M.; Aakerman, L.; et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001, 61, 2062-2070.
21. Hao, S.; Moyana, T.; Xiang, J. Cancer immunotherapy by exosomebased vaccines. Cancer Biother Radiopharm 2007, 22, 692-703.
22. Li, N.; Qin, H.; Li, X.; Zhou, C. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumorassociated antigen gene-modified tumor cell and blockade of B7- H1. J Clin Immunol 2007, 27, 117-130.
23. Liang, C.M.; Zhong, C.P.; Sun, R.X. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 2007, 81, 9502-9511.
24. Van Nimwegen, M.J.; Verkoeijen, S.; Kuppen, P.J. An improved method to study NK-independent mechanisms of MTLn3 breast cancer lung metastasis, Clin Exp Metast 2007, 24, 379-387.
25. Schenck, M.; Börgermann, C.; Jäger, T. Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferonalpha2a, and erythropoietin-beta. Urologe A 2007, 46, 528-534.
26. Margolin, K.A. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000, 27, 194-203.
27. Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17, 2105-2116.
28. Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.;Marincola, F.M. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4, 321-327.
29. Matsuyoshi, H.; Senju, S.; Hirata, S. Enhanced priming of antigenspecific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004, 172, 776-786.
30. Kirk, C. J.; Hartigan-O'Connor, D.; Nickoloff, B.J.; Mule J. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001, 61, 2062.
31. Mahnke, K.; Ring, S.; Johnson, T.S.; Schallenberg, S. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol 2007, 37, 2117-2126.
32. Sharma, S.; Stolina, M.; Luo, J.; et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000, 164, 4558-4563.
33. Eo, S.K.; Lee, S.; Kumaraguru, U. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands, Vaccine 2001, 19, 4685-4693. (Pubitemid 32800751)
34. He, Y.F.; Zhang, G.M.; Wang, X.H.; Zhang, H. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 2004, 173, 4919-4928.
35. Abu-Khalaf, M.M.; Wheler, J.; Zerkowski, M.; et al. High expression of the chemokine receptor CCR7 is associated with worse outcome in breast cancer. ASCO Meet Abstr 2005, 23, 9593.
36. Takeuchi, H.; Fujimoto, A.; Tanaka, M. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004, 10, 2351-2358.